ArticleGut2018
FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma.
6 registry-linked trialsAbstract readLetterComment
In one paragraph
Article in Gut, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 6 registered trials, which are not on this map. Cited by 72 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 3 pooled it
1.9field-weighted citation impact, top 14% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT03869034 phase2active not recruitingnot on this mapstarted 2019, after this paper: background citation
Hepatic Arterial Infusion Chemotherapy Combined with PD-1 Inhibitor in Treating Potentially Resectable Locally Advanced Hepatocellular Carcinoma: a Prospective, Phase II Clinical Study
An Open Label Pilot Study to Evaluate Efficacy and Safety of Durvalumab(MEDI 4736) With Hepatic Artery Infusion Chemotherapy (HAIC) in the Chinese Advanced HCC Patients With Severe Portal Vein Tumor Thrombosis (PVTT)(Vp3 or Vp4) DurHope
Observational Study of Factors Predicting Therapeutic Effects and Clinical Prognosis After Hepatic Artery Infusion Chemotherapy (HAIC) for Locally Advanced Hepatocellular Carcinoma (HCC)
A Prospective, Multicenter, Phase III Clinical Study Comparing Continuous Hepatic Arterial Infusion of Raltetrexed With Oxaliplatin(SALOX) Versus FOLFOX in Advanced Hepatocellular Carcinoma
Observation Study of Sequential Regorafenib Combined With Immunocheckpoint Inhibitors After Hepatic Artery Infusion Chemotherapy for Advanced Hepatocellular Carcinoma
A Study of the Application of Hepatic Arterial Infusion in Advanced Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors and Antiangiogenic Agents
Who cites it
72 citing papers in PubMed, 3 syntheses or guidelines pooled it, 132 citations in OpenAlex.
- Potential of neoadjuvant hepatic artery perfusion chemotherapy in improving surgical outcomes in hepatocellular carcinoma: a systematic review and meta-analysis.World journal of surgical oncology · 2025Pooled it
- Pooled it
- Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.Frontiers in bioengineering and biotechnology · 2022Pooled it
- Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study.Nature communications · 2026Trial
- Trial
- Hepatic arterial infusion or intravenous infusion of adebrelimab, combined with bevacizumab and HAIC of the FOLFOX regimen for advanced unresectable hepatocellular carcinoma (HAIBrave-001 trial): a study protocol of a prospective, double-arm, phase II trial.Journal of gastrointestinal oncology · 2026Article
- Epidemiological characteristics of Helicobacter pylori infection in Shizuishan and its association with colorectal cancer and the gut microbiota.Tropical medicine and health · 2026Article
- Article
- Efficacy of Locoregional HAIC and Systemic Treatment for Treatment- Naive Unresectable Hepatocellulcar Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Safety and efficacy of transcatheter chemoembolization combined with hepatic arterial infusion chemotherapy for unresectable primary liver cancer: a single-center prospective study.Journal of gastrointestinal oncology · 2025Article
- Dual roles of USP1 in HELLS deubiquitination and SUMOylation drive EMT and FOLFOX-based chemoresistance.Oncogenesis · 2025Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Radiological characteristics for guiding intra-arterial therapy in intermediate-stage hepatocellular carcinoma.BMC medicine · 2025Article
- Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study.Scientific reports · 2025Article
- Neoadjuvant hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin for resectable single large hepatocellular carcinoma.International journal of surgery (London, England) · 2025Article
- The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma.Cancer management and research · 2025Article
- PD-1 inhibitor-augmented HAIC-TKI therapy in hepatocellular carcinoma with portal vein tumor thrombosis: real-world survival benefits, safety, and subgroup-specific efficacy.Frontiers in immunology · 2025Article
- Risk Factors and Predictive Analysis of Acute Severe Abdominal Pain After Hepatic Artery Infusion Chemotherapy in Patients with Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
- Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus.Journal of hepatocellular carcinoma · 2025Article
- Development of Cytolytic Iridium-Complexed Octaarginine Peptide Albumin Nanomedicine for Hepatocellular Carcinoma Treatment.International journal of nanomedicine · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
- Comment on
Authors and funding
15 authors at 3 institutions in 1 country.
Ning LyuDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Youen LinDepartment of Interventional Radiology, Jieyang Affiliated Hospital, Sun Yat-sen University, Jieyang, China.
Yanan KongState Key Laboratory of Oncology in South China, Sun Yat-sen University Cancer Center, Guangzhou, China.
Zhenfeng ZhangDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Longzhong LiuDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Lie ZhengDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Luwen MuDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Jianpeng WangDepartment of Minimally Invasive Interventional and Target Treatment, Affiliated Foshan Hospital of Sun Yat-sen University, Foshan, China.
Xishan LiDepartment of Interventional Radiology, First People's Hospital, Guangzhou, China.
Tao PanDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Qiankun XieDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Yaru LiuDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Aihua LinDepartment of Medical Statistics and Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou, China.
Peihong WuDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Ming ZhaoDivision of Minimally Invasive Interventional, Department of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, Guangzhou, China.
Sun Yat-sen University · CNSun Yat-sen University Cancer Center · CNGuangzhou Medical University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Carcinoma, HepatocellularLeucovorinAntineoplastic Combined Chemotherapy ProtocolsCisplatinFluorouracilHumansLiver NeoplasmsOrganoplatinum CompoundsOxaliplatinTreatment OutcomeCisplatinFluorouracilLeucovorinOrganoplatinum CompoundsOxaliplatinAdvanced HCCFOLFOXHAIC
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT03869034ClinicalTrials.gov
NCT04945720ClinicalTrials.gov
NCT05002452ClinicalTrials.gov
NCT05231382ClinicalTrials.gov
NCT05573282ClinicalTrials.gov
NCT05718492ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.